New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:03 EDTMRKMerck announces presentation of MK-3475 new data
Merck announced that new data for the company’s investigational anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung cancer, and head and neck cancer, are scheduled to be presented on May 30 – June 3. The first presentation of data for MK-3475 as initial treatment in advanced NSCLC, where chemotherapy is currently the standard of care, and for the treatment of advanced head and neck cancer will be part of oral sessions at ASCO 2014. The broad MK-3475 dataset to be highlighted across multiple tumors and lines of therapy comprises 16 abstracts, with half being oral presentations or poster discussions. On May 6, Merck announced that the Biologics License Application for MK-3475 has been accepted for priority review by the U.S. Food and Drug Administration fpr the treatment of patients with advanced melanoma previously-treated with ipilimumab, the PDUFA date is October 28. The company also announced plans to file a Marketing Authorization Application for MK-3475 for advanced melanoma in Europe by the end of FY14.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:39 EDTMRKMerck says Phase 3 Emend data shows it provides 'greater protection' from nausea
Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose Emend for Injection, Merck’s substance P/neurokinin receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting, or CINV, in adult cancer patients receiving moderately emetogenic chemotherapy, or MEC. In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose Emend for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on “Supportive Care in Cancer” in Copenhagen.
June 24, 2015
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use